RPS17P2: A Ribosomal Protein Target for Drug Development (G6219)

Target Name: RPS17P2

NCBI ID: G6219

RPS17P2

Other Name(s): Ribosomal protein S17 pseudogene 2 | RPS17_5_604 | RPS17A | ribosomal protein S17 pseudogene 2 | RPS17L1

RPS17P2: A Ribosomal Protein Target for Drug Development

Introduction

Ribosomal protein S17 (RPS17) is a key protein that contributes to the stability and integrity of the ribosome, the site of protein synthesis in eukaryotic cells. RPS17 has been implicated in various cellular processes, including cell growth, apoptosis, and autophagy. The identification of RPS17 as a potential drug target has significant implications for the development of new therapeutic approaches. In this article, we will explore the biology of RPS17 and its potential as a drug target, with a focus on the scientific literature and current research.

Biogenesis and Functions of RPS17

RPS17 is a 21-kDa protein that belongs to the Ribosomal Protein family 17 (RPL17). RPL17 is synthesized in eukaryotic cells using the same machinery as other ribosomal proteins,21 including cytosine synthosis,22 which leads to the formation of a stable 21- kDa protein with a C-terminal hypervariable region (HVR).23 The HVR of RPS17 is rich in conserved amino acid sequence,24 which allows it to interact with various molecules, including other ribosomal proteins and microtubules.25

RPS17 plays a crucial role in the stability and integrity of the ribosome. It helps to maintain the proper size and shape of the ribosome,26 and is involved in the formation of the rRNA secondary structure,27 which is essential for the initiation of protein synthesis .28 Additionally, RPS17 is involved in the regulation of rRNA translation,29 which is critical for the production of functional proteins.30

In addition to its role in the ribosome, RPS17 has been shown to participate in various cellular processes. For example, RPS17 has been involved in the regulation of cell growth and apoptosis,31 cell division,32 and autophagy.33

Mutations in RPS17 have been linked to various diseases, including cancer,34 neurodegenerative diseases,35 and diseases associated with protein misfolding.36 Therefore, the study of RPS17 has significant implications for the development of new therapeutic approaches.

Potential Drug Targets for RPS17

The identification of RPS17 as a potential drug target has significant implications for the development of new therapeutic approaches. Several studies have identified potential drug targets for RPS17, including:

1. Modulation of RPS17 expression levels: Several studies have shown that drugs can modulate the expression levels of RPS17, leading to changes in cellular behavior. For example, inhibitors of the translation machinery have been shown to decrease RPS17 expression,37 whereas drugs that enhance the translation machinery have been shown to increase RPS17 expression.38

2. Interaction with RPL17: Several studies have shown that drugs can interact with RPL17, leading to changes in cellular behavior. For example, inhibitors of the poly(A) polymerase (DNA damage-inducible GFP-伪) have been shown to decrease the interaction between RPL17 and DNA,39 whereas drugs that enhance the poly(A) polymerase have been shown to increase the interaction.40

3. modulation of RPS17 function: modulation of RPS17 function by drugs can also be a potential drug target. For example, inhibitors of RPS17-associated protein have been shown to decrease the activity of RPS17,41 whereas drugs that enhance the activity of RPS17 have been shown to increase it.42

4.

Protein Name: Ribosomal Protein S17 Pseudogene 2

The "RPS17P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS17P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets